Get started
KalVista Pharmaceuticals, Inc.

$KALV Reports Positive Results for KVD900 Phase 2

By AlenCiken
KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) –

– KVD900 Generally Safe and Well-Tolerated –

There were no serious adverse events reported in the trial and no patients withdrew due to adverse events.

finance.yahoo.com/news/kalvista-pharmaceuticals-reports-positive-results-113000067.html
biotechbiotechnologybiotechsbiotechstockbiotechstocksbiotehnologyChart PatternsFundamental AnalysisTrend Analysis
AlenCiken
Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.